MT204 

MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy^[1].

MT204 (1-100 μg/mL, 4 days) dose-dependently inhibits proliferation and IFN-γ secretion in rhesus PBMCs stimulated by the mitogen concavalin A^[1].
MT204 can block CD25-bound IL-2 on high-affinity IL-2 receptors with a k_d of 0.58 nM^[1][2].
MT204 (5 h) dose dependently reduces the IL-2 inducible cell surface expression of the alpha subunit of IL-4 receptor (CD124) in CTLL-2 cells^[2].
MT204 (5 days) inhibits IL-2-induced proliferation of NKL cells and T cells with IC₅₀ s of approximately 1.3 nM and 0.21 nM, respectively^[2].
MT204 (15 min) potently antagonizes downstream signaling of IL-2 at sub-nanomolar concentrations, significantly reducing cellular pY-STAT3 levels stimulated by IL-2 in Primary human lymphocytes^[2].
MT204 significantly inhibits IL-2 induced proliferation independently of CD25 expression levels in NKL cells, T cells and all NK cells with IC₅₀ s of 0.35-0.36 nM, 0.33 nM, and 0.1-0.13 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MT204 (50  mg/kg, i.v., day 0, day 5 and day 12 at a speed of 1.5 mL/kg/h over 1 h) significant delays in rejection of allogeneic skin graft in allogeneic skin graft model of rhesus monkey^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Plater-Zyberk C, et al. The interleukin-2 antagonizing antibody MT204 delays allogeneic skin graft rejection in non-human primates and is well tolerated. Transpl Immunol. 2011 Sep; 25(2-3):133-40.  [Content Brief]

  [2]. Volkland J, et al. A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. Mol Immunol. 2007 Mar; 44(7):1743-53.  [Content Brief]